X4 Pharmaceuticals (XFOR) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$15.8M

Revenue (quarter)

$8.8M

Revenue growth (year over year)

+346.33%

Gross profit (trailing twelve months)

$12.9M

Gross margin

81.51%

Net income (trailing twelve months)

−$90.1M

Net income (quarter)

−$16.2M

Net income growth (year over year)

+37.23%

Net margin

−568.80%

Return on equity

−113.08%

EPS (trailing twelve months)

$1.43

Book value per share

$1.62

P/E (trailing twelve months)

—

Price to book

1.56

Debt to assets

38.57%

Payout ratio

—

Dividend yield

—

Company profile

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

• Is X4 Pharmaceuticals (XFOR) profitable?

  No. X4 Pharmaceuticals reported a net loss of $90.1M over the trailing twelve months.

• How much revenue does X4 Pharmaceuticals (XFOR) make?

  X4 Pharmaceuticals generated $15.8M in revenue over the trailing twelve months, up 346.33% year over year.

• How do I buy stock in X4 Pharmaceuticals (XFOR)?

  XFOR trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.